Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (DE:82P)
FRANKFURT:82P
RESEARCH TOOLSreports
Pacira Pharmaceuticals (82P) Stock Price & Analysis
0 Followers
82P Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€23.80 - €42.80
Previous Close€24.2
Volume0.00
Average Volume (3M)240.00
Market Cap
€1.14B
Enterprise Value€1.47B
Total Cash (Recent Filing)$235.19M
Total Debt (Recent Filing)$590.30M
Price to Earnings (P/E)N/A
Beta0.58
Next Earnings
May 01, 2024EPS Estimate
€0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,500,778
10 Day Avg. Volume0
30 Day Avg. Volume240
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.46
Price to Sales (P/S)1.70
Price to Cash Flow (P/CF)6.40
P/FCF Ratio6.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.21
Enterprise Value/Gross Profit2.24
Enterprise Value/Ebitda14.29
Forecast
1Y Price Target
€43.35Price Target Upside79.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Pacira Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Legislative SupportThe NOPAIN Act and the approval of the drug for lower extremity surgeries are expected to accelerate the uptake of Exparel.
Financial GrowthProjected revenue growth for Pacira is almost 10% annually, increasing from $675MM to approximately $1.25bn in 2030.
Strategic Partnerships And GrowthPacira announced a national Brand Pharmaceuticals group purchasing organization (GPO) agreement with Premier, Inc., which is expected to drive further EXPAREL volume expansion.
Bears Say
Profitability ConcernsThe expected modest gross margin expansion for 2024 is below current consensus expectations, which may raise concerns about profitability.
Revenue Growth ForecastPCRX's modest revenue growth forecast for 2024 is below consensus, indicating potential concerns about the company's growth trajectory.
Sales PerformanceExparel's market penetration has fallen short of investor expectations with sales growing by only 6% year-over-year.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.21% Other Institutional Investors
98.79% Public Companies and
Individual Investors
82P FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was €23.80 and its highest was €42.80 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Currently, no data Available
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is May 01, 2024 which is in 6 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Feb 29, 2024. The company reported €0.834 earnings per share for the quarter, beating the consensus estimate of €0.828 by €0.007.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is €0.59.
How many shares outstanding does Pacira Pharmaceuticals have?
Currently, no data Available
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of €0.834 in its last earnings report, beating expectations of €0.828. Following the earnings report the stock price went up 0.735%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Among the largest hedge funds holding Pacira Pharmaceuticals’s share is Ardsley Advisory Partners. It holds Pacira Pharmaceuticals’s shares valued at 10M.
---
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€43.35 (79.14% Upside)
€43.35 (79.14% Upside)
Blogger Sentiment
Bullish
DE:82P Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $3.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.05%
12-Months-Change
Fundamentals
Return on Equity
5.10%
Trailing 12-Months
Asset Growth
-6.35%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
---
82P Company Deck
---
82P Earnings Call
Q4 2024
0:00 / 0:00
---
82P Stock 12 Months Forecast
Average Price Target
€43.35
▲(79.14% Upside)
Technical Analysis
Best Analysts Covering 82P
1 Year
1 Year Success Rate
10/26 ratings generated profit
1 Year Average Return
-2.00%
reiterated a buy rating 6 months ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -2.00% per trade.
---